Novartis collaboration for KAF156 with Medicines for Malaria Venture (MMV)

Novartis AG, a Switzerland-based drug maker, announced that it will further expand its long-standing partnership with Medicines for Malaria Venture (MMV). Under the collaboration, Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation. The agreement sets out the terms and conditions for the development of drug and its future availability to patients.